A Phase 1 interventional study of ALXN1850 in Hypophosphatasia, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hypophosphatasia by AstraZeneca — 4 open to participants now, 7 under way, 3 of them phase 3. Hypophosphatasia · AstraZeneca.
Among the 25 studies in Hypophosphatasia by AstraZeneca, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 1, and was the 18th registered.
46 studies on the registry are indexed under Hypophosphatasia; 11 are open to participants now.
Browse Hypophosphatasia studies →4 of the 25 studies in Hypophosphatasia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
AstraZeneca · Sites in Russia
Alexion Pharmaceuticals, Inc. · Sites in United States
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, Austria and 10 more countries
By country, each count listing its studies:
Of the 9 Hypophosphatasia studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is close to the median of 14 across 18 interventional studies indexed under Hypophosphatasia.
Median enrollment 13 across the 16 interventional studies, 49 across the 8 observational. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Hypophosphatasia by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.
Biological: ALXN1850
ALXN1850 will be administered as an IV infusion and via the SC route.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
TEAEs were defined as any adverse events (AEs) that began or worsened on or after the first dose of treatment until the final follow-up visit. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. TESAEs were defined as any serious AEs that began or worsened on or after the first dose of treatment until the final follow-up visit. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 85
Maximum Observed Plasma Concentration (Cmax) of ALXN1850 Following Intravenous (IV) Dose, Subcutaneous (SC) Dose 1, SC Dose 2 and SC Dose 3
Time frame: Predose, 2, 6 and 12 hours postdose on Days 1, 15, 22 and 29
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity Following IV Dose of ALXN1850
Time frame: Predose, 2, 6 and 12 hours postdose on Days 1, 15, 22 and 29
Area Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Following SC Dose 1, SC Dose 2 and SC Dose 3
Time frame: Predose, 2, 6 and 12 hour postdose on Days 1, 15, 22 and 29
Area Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Values of the First SC Versus IV Administration of ALXN1850
Time frame: Predose, 2, 6 and 12 hour postdose on Days 1, 15, 22 and 29
Absolute Change From Baseline in Plasma Concentration of Pyridoxal-5' Phosphate (PLP) at Week 1
Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Absolute Change From Baseline in Plasma Concentration of Inorganic Pyrophosphate (PPi) at Week 1
Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Absolute Change From Baseline in Plasma Concentration of Pyridoxal Phosphate/ Pyridoxal (PLP/PL) Ratio at Week 1
Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Percent Change From Baseline in Plasma Concentration of PLP at Week 1
Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Percent Change From Baseline in Plasma Concentration of PPi at Week 1
Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Percent Change From Baseline in Plasma Concentration of PLP/PL Ratio Over Time at Week 1
Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Number of Participants With Anti-drug Antibody (ADA) Positive and Neutralizing Antibody (NAb) Positive Status
Time frame: Baseline up to Day 85
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Received at least 1 dose of study drug | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
TEAEs were defined as any adverse events (AEs) that began or worsened on or after the first dose of treatment until the final follow-up visit. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. TESAEs were defined as any serious AEs that began or worsened on or after the first dose of treatment until the final follow-up visit. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| TEAEs | 3 | 5 | 4 |
| TESAEs | 0 | 0 | 1 |
| micrograms/milliliter | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| IV Dose | 5.31 ± 29.2 | 13.5 ± 23.3 | 32.4 ± 31.1 |
| SC Dose 1 | 0.871 ± 43.8 | 2.89 ± 59.4 | 8.60 ± 43.5 |
| SC Dose 2 | 0.815 ± 52.3 | 2.38 ± 88.8 | 6.33 ± 55.5 |
| SC Dose 3 | 0.844 ± 75.2 | 2.41 ± 97.4 | 5.44 ± 145 |
| hour*micrograms/milliliter | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity Following IV Dose of ALXN1850 | 407 ± 38.3 | 1010 ± 26.0 | 2450 ± 33.6 |
| hour*micrograms/milliliter | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| SC Dose 1 | 115 ± 42.2 | 383 ± 58.1 | 1110 ± 49.6 |
| SC Dose 2 | 111 ± 58.5 | 350 ± 83.3 | 872 ± 65.5 |
| SC Dose 3 | 115 ± 73.9 | 367 ± 95.6 | 881 ± 104 |
| Ratio | All Participants |
|---|---|
| 15 mg | 0.286 (0.105 to 0.782) |
| 45 mg | 0.367 (0.180 to 0.784) |
| 90 mg | 0.368 (0.0908 to 1.49) |
| nanogram/milliliter | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| 1 Week post Day 1 IV Dose | -18.300 ± NA | -7.600 ± NA | -49.460 ± NA |
| 1 Week post Day 29 SC Dose 3 | -97.950 ± 164.0193 | -38.573 ± 26.4932 | -28.055 ± 17.3237 |
| micromoles (uM) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| 1 Week post Day 1 IV Dose | -1.620 ± NA | -1.930 ± NA | — |
| 1 Week post Day 29 SC Dose 3 | -0.813 ± 0.5970 | -1.505 ± 0.1202 | -2.040 ± NA |
| Ratio | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| 1 Week post Day 1 IV Dose | -8.570 ± NA | -16.070 ± NA | -15.260 ± NA |
| 1 Week post Day 29 SC Dose 3 | -7.620 ± 5.3878 | -15.285 ± 6.2807 | -8.368 ± 6.3951 |
| percent change | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| 1 Week post Day 1 IV Dose | -47.906 ± NA | -17.512 ± NA | -86.318 ± NA |
| 1 Week post Day 29 SC Dose 3 | -33.895 ± 42.5254 | -69.049 ± 16.5385 | -70.515 ± 23.0447 |
| percent change | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| 1 Week post Day 1 IV Dose | -53.821 ± NA | -70.956 ± NA | — |
| 1 Week post Day 29 SC Dose 3 | -32.740 ± 23.0615 | -55.328 ± 1.7622 | -71.329 ± NA |
| percent change | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| 1 Week post Day 1 IV Dose | -65.270 ± NA | -92.944 ± NA | -91.323 ± NA |
| 1 Week post Day 29 SC Dose 3 | -35.104 ± 15.0384 | -77.160 ± 16.0636 | -60.816 ± 49.7578 |
| Participants | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| ADA Positive | 2 | 0 | 2 |
| NAb Positive | 0 | 0 | 0 |
Collected over Baseline up to Day 85. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort 2 | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Cohort 3 | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/5 | 0/5 | 1/5 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| HeadacheMusculoskeletal and connective tissue disorders | 1/5 | 2/5 | 0/5 |
| Coronavirus infectionInfections and infestations | 0/5 | 1/5 | 2/5 |
| HyperphosphataemiaMetabolism and nutrition disorders | 2/5 | 0/5 | 0/5 |
| HaematuriaRenal and urinary disorders | 0/5 | 2/5 | 0/5 |
| FatigueGeneral disorders | 1/5 | 1/5 | 0/5 |
| Injection site bruisingGeneral disorders | 1/5 | 1/5 | 0/5 |
| Injection site erythemaGeneral disorders | 0/5 | 1/5 | 1/5 |
| Injection site haemorrhageGeneral disorders | 0/5 | 1/5 | 0/5 |
| Injection site pruritusGeneral disorders | 0/5 | 1/5 | 0/5 |
| Injection site reactionGeneral disorders | 1/5 | 0/5 | 0/5 |
The Safety Set included all participants who received any amount of study drug. Participants were analyzed according to the study drug received.
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 44.2 ± 12.44 | 37.8 ± 12.52 | 54.6 ± 9.07 | 45.5 ± 12.80 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 5 | 11 |
| Male | 2 | 2 | 0 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 5 | 5 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 5 | 5 | 15 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Aug 2022, 10 months.
Results were first posted in Dec 2024, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efzimfotase alfa
Alexion Pharmaceuticals, Inc. →